Esperion Therapeutics (NASDAQ: ESPR) reported Q4 EPS of ($0.50), $0.03 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $32.25 million versus the consensus estimate of $28.58 million.

2024 Financial Outlook:
The Company expects full year 2024 operating expenses to be approximately $225 million to $245 million, including $20 million in non-cash expenses related to stock compensation.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.